WallStreetZenWallStreetZen

NASDAQ: EMBC
Embecta Corp Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Embecta earnings were $95.4M for the trailing 12 months ending Sep 30, 2025, with 20.6% growth year over year. The latest EMBC earnings report on Sep 30, 2025 announced Q3 2025 earnings of $26.4M, down 42% from last quarter. For the last reported fiscal year 2025 ending Sep 30, 2025, EMBC reported annual earnings of $95.4M, with 21.8% growth. The next EMBC earnings date is Feb 6, 2026.

EMBC past earnings growth

How has EMBC's earnings growth performed historically?

Company
20.59%
Industry
10.95%
Market
53.6%
EMBC's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
EMBC's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
EMBC's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

EMBC earnings history

Current Revenue
$1.1B
Current Earnings
$95.4M
Current Profit Margin
8.8%

EMBC Return on Equity

Current Company
-13.5%
Current Industry
9.6%
Current Market
35.1%
EMBC's Return on Equity (-13.5%)... subscribe to Premium to read more.
High Return on Equity Performance

EMBC undefined

Current Company
8.4%
Current Industry
8.3%
EMBC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when EMBC announces earnings.

EMBC undefined

Current Company
29.37%
Current Industry
11.1%
EMBC's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EMBC vs Medical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
EMBC$294.70M$95.40M-26.22%$1.64
ANGO-$6.24M-$32.10MN/A-$0.78
PLSE-$72.79M-$74.73MN/A-$1.14
KRMD-$2.85M-$3.71MN/A-$0.08
STXS-$22.10M-$24.91MN/A-$0.28
View Top Medical Stocks

EMBC earnings dates

Next earnings date
Feb 6, 2026

Embecta Earnings Reports & History FAQ

What were Embecta's earnings last quarter?

On EMBC's earnings call on Invalid Date, Embecta (NASDAQ: EMBC) reported Q3 2025 earnings per share (EPS) of $0.46, up 84% year over year. Total EMBC earnings for the quarter were $26.40 million. In the same quarter last year, Embecta's earnings per share (EPS) was $0.25.

If you're new to stock investing, here's how to buy Embecta stock.

When does Embecta report earnings?

The next EMBC earnings date is Invalid Date. Add EMBC to your watchlist to be reminded of Embecta's next earnings date.

Is Embecta profitable or losing money?

As of the last Embecta earnings report, Embecta is currently profitable. Embecta's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $95.40 million, a 21.84% increase year over year.

What was EMBC's earnings growth in the past year?

As of Embecta's earnings date in Invalid Date, Embecta's earnings has grown 20.59% year over year. This is 9.64 percentage points higher than the US Medical Instruments & Supplies industry earnings growth rate of 10.95%. EMBC earnings in the past year totalled $95.40 million.

What are Embecta's earnings expectations?

The current EPS estimate for Embecta's earnings report in Invalid Date is $0.71.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.